Anti-cancer drugs

            The information of this article is obsolete.
          Please check
FDA website for information.                                                  

AMN 107 AMN107, an investigational drug, is producing powerful responses in
patients diagnosed with chronic myeloid leukemia, resistant to Gleevec. Novartis is the
manfacturers for both AMN107 and Gleeve.
Increasing Benefit Seen in Novel Drug That Treats Gleevec Resistance, Newswise,
April 13, 2005. Source University of Texas M.D. Anderson Cancer Center
.

AVASTIN (BEVACIZUMAB) Colorectal cancer is the third most common cancer.
Approximately 147,500 new cases were diagnosed in 2003.
AVASTIN is the first line
treatment for patients with metastatic colorectal cancer.

The interim results of a late-stage trial showed that Avastin was successful when used
with chemotherapy in untreated breast cancer which has spread to other parts of the
body. About 8-9% of women will develop breast cancer during their lifetime.
Roche's Avastin Works in Third Type of Cancer, Reuters, April 15, 2005

Avastin has achieved sales of $469 million in the first half of 2005.
Pfizer seeks approval for cancer drug Reuters Aug 10 2005.

THALIDOMIDE Multiple myeloma affects about 50,000 American. About 14,600 new
cases occur annually. Celgene's thalidomide was found to be effective for treating
patients with multiple myeloma, a form of blood cancer in a phase III trial.
Celgene Says
Blood Cancer Patients Respond to Drug, Reuters, June 7, 2004.

ERBITUX About 40,000 Americans are diagnosed each year with oral, head and neck
cancers. Radiation is a standard treatment. Tumors were less likely to spread in
patients who took ImClone Systems' Erbitux in combination with radiation. Erbitux
works by blocking a protein called epidermal growth factor which helps tumor cells
reproduce.
Erbitux Prolongs Survival in Head and Neck Cancer, Ransdell Pierson,
Reuters, June 5, 2004.

PROXINIUM Viventia initates a second Phase I clinical trial for treatment of head and
neck cancer with Proxinium.
Press Release, June 7, 2004

TAXOTERE 230,900 new cases of prostate cancer may occur this year in the United
States. It was found that men with aggressive prostate cancer treated with Aventis'
Taxotere lived longer than patients treated with other standard chemotherapy drugs in
Phase III trials.  
Related News Aventis Drug Prevails in Prostate Cancer Trials, by
Pierson et al, Reuters, Jun 7, 2004.

HERCEPTIN A recent study showed that Herceptin, an antibody-based drug, helps
women fight an aggressive form of early-stage breast cancer after surgery. The
estimated sales for Herceptin in 2009 is about 4.2 billion francs.
Roche's Breast Cancer Drug Gets More Positive Data, Reuters, April 28, 2005.

SORAFENIB
Bayer and Onyx completed their US marketing application for sorafenib. Sorafenib
blocks RAF kinase and VEGF that helps produce blood vessels which feed tumors.
The market for sorafenib can be as high as $600 million after launching. [3]

Pfizer's SUTENT/SU11248 (sunitinib malate)
Sutent pill is developed to treat gastrointestinal stromal tumors, a type of stomach
cancer, and kidney cancer that has spread to other parts of the body and not been
controlled by standard treatments. Sutent might have significant advantages over
existing treatments. [1 For instance, new study shows Pfizer's SUTENT/SU11248
(sunitinib malate) extends overall survival in Novartis AG's Gleevec-resistant GIST. [2]
About 5000-10,000 Americans were diagnosed with this cancer. [3]

Sutent is one of the first in a new class of drugs that selectively targets multiple protein
receptors, called receptor tyrosine kinases. Tyrosine kinases may be a molecular
switch for cancer growth. Inhibition of these tyrosine kinases is believed to starve
tumors of blood and nutrients needed for growth and simultaneously kill the cancer cells
that make up tumors.

The FDA has granted Sutent fast-track status for review and Pfizer planned to seek
FDA approval by August for the pill.

[1] Pfizer Submits Application for Sutent to FDA PR Wed Aug 10, 2005
[2] New data show Pfizer's SUTENT/SU11248 (sunitinib malate) extends overall
survival in Gleevec-resistant GIST Globandmail.com Aug 10, 2005 [3] Pfizer seeks
approval for cancer drug Reuters Aug 10 2005.

VACCINE Merck & Co is developing a vaccine called Gardasil which can protect
women against four strains of the human papillomavirus (HPV). The papillomavirus are
prime cause of cervical cancer and genital warts. The new vaccine may reach the
market in 2006 to compete with GlaxoSmithKline's Cervarix. Merk is partnering with
Sanofi-Aventis to seek first regulatory approvals for its vaccine in Europe. Currently, the
cervical cancer victimizes about 470,000 women a year.
A vaccine for cervical cancer
found, Earthtimes.org, April 5, 2006
As  the  technologies improve, more new anticancer drugs with less side-effects are available in the market.
This web-site collects and summarizes news and research findings about recently developed  anti-cancer drug
products.
New Anti-cancer Drugs
THIS WEBSITE TALKS ABOUT THE SIDE EFFECTS AND THE POTENTIAL HEALTH BENEFITS OF HERBS,
SUPPLEMENTS, PHYTONUTRIENTS AND DRUG PRODUCTS. THIS WEBSITE ALSO TALKS ABOUT SOME
POPULAR HEALTH ISSUES AND DISEASES. ARTICLES IN THIS WEB SITE IS FOR YOUR REFERENCE ONLY.
IF YOU HAVE ANY QUESTION, YOU SHOULD CONSULT WITH YOUR DOCTOR IMMEDIATELY. ALL RIGHTS
RESERVED 2008. DO NOT COPY NOR TRANSFER ARTICLES TO OTHER WEBSITES NOR OTHER FORMS OF
PUBLICATIONS.
Privacy Policy. ARTICLE INDEX